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Abstract
Background: The transcription factor nuclear factor (erythroid-2)–related factor 2 (Nrf2) was originally identified
as a critical regulator of intracellular anti-oxidants and of phase II detoxification enzymes through its transcriptional
up-regulation of many anti-oxidant response element (ARE)-containing genes. Nrf2 protects not only normal cells
but also cancer cells from cellular stress, and enhances cancer cell survival. Some studies have shown that Nrf2
expression in cancer patients has clinical significance. However, there has been no comprehensive analysis of the
nuclear expression level of Nrf2 in gastrointestinal cancer cells. In this study we aimed to immunohistochemically
evaluate the expression of Nrf2, and to assess its clinical significance in gastric cancer.
Methods: A total of 175 gastric cancer patients who received R0 gastrectomy with standard lymph node dissection were
enrolled. We immunohistochemically evaluated Nrf2 expression in the paraffin-embedded surgically resected specimens
of these 175 patients. Group differences were analyzed using the χ2 test, Fisher’s exact test, and the Mann–Whitney U test.
Associations between Nrf2 expression and clinicopathological features, including clinical outcome, were assessed using
univariate and multivariate analyses, and Kaplan-Meier curves with the log-rank test, respectively.
Results: Nrf2 immunoreactivity was predominantly identified in the nucleus of gastric cancer cells. Nrf2 positivity was
closely associated with tumor size, tumor depth, lymph node metastases, lymphovascular invasion, histology and stage
(p < 0.05 for all). A log-rank test indicated that the overall survival of the Nrf2-positive group was significantly poorer than
that of the Nrf2-negative group (p < 0.01). And, positive Nrf2 expression was significantly associated with resistance to
5FU-based adjuvant chemotherapy (p = 0.024).
Conclusions: Nrf2 expression was positively associated with aggressive tumor behavior in gastric cancer. This result
suggests that Nrf2 expression in gastric cancer is a potential indicator of worse prognosis.
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Background
Gastric cancer is the fourth-most common gastrointes-
tinal cancer and the second-most common fatal gastro-
intestinal cancer in the world. East Asian countries
including Japan are among the highest-risk areas for gas-
tric cancer [1,2]. In Japan, the establishment of mass
screening using photo fluoroscopy or gastrointestinal
fibroscopy has led to gastric cancer being diagnosed at
early stages. A favorable prognosis is expected for these
gastric cancer patients following curative surgery or
endoscopic treatment. However, some patients show an
unfavorable course despite receiving curative resection.
The postoperative outcome of gastric cancer strongly
depends on TNM factors [3,4]. In addition to these critical
clinicopathological factors, the prognosis of gastric carcin-
oma is influenced by several biological variables. In this
context, it is necessary to find novel cancer-related fac-
tors that can be used as markers for the diagnosis and
treatment of gastric cancer. It is generally accepted that
oxidative stress (OS) is involved in the pathophysiology
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of degenerative diseases. Moreover, the generation and
increase of OS and secondary DNA oxidative damage are
also known to be related to the damage and malignant
transformation of gastric mucosa [5]. Thus, OS has been
considered to play important roles in the carcinogenesis
of gastric cancer [5,6].
The transcription factor nuclear factor (erythroid-2)–
related factor 2 (Nrf2), which is a basic redox-sensitive
bZIP transcription factor, was originally identified as a
critical regulator of intracellular antioxidants and of phase
II detoxification enzymes through the transcriptional up-
regulation of many antioxidant response element (ARE)
-containing genes [7-9] . Under basal conditions, Nrf2 is
bound to the kelch-like ECH-associated protein 1 (Keap1),
a cul3-based E3 ubiquitin ligase adapter that regulates
Nrf2 ubiquitination and proteasome-dependent degrad-
ation [10].
Upon exposure of cells to oxidative stress or chemo-
preventive compounds, Nrf2 translocates to the nucleus,
forms a heterodimer with its obligatory partner Maf,
binds to the ARE sequences in DNA and activates the
transcription of downstream genes such as antioxidants
and phase II detoxification enzymes [8,11-13]. The im-
portant biological role of Nrf2 is underlined by findings
demonstrating Nrf2-dependent protection against many
human diseases or pathological states such as cancer,
neurodegenerative diseases, cardiovascular disease, in-
flammation, pulmonary fibrosis, acute pulmonary injury
and Nrf2 also slows the process of aging [14-18]. Thus
Nrf2 has been considered as a “good” transcription factor
that is essential for protection against oxidative stress [19].
However, emerging data has revealed the dark side of
Nrf2 [20]. It has recently been shown that aberrant activa-
tion of the Nrf2 pathway occurs frequently in cancer cells
and tumor tissues. Nrf2 protects not only normal cells
from transforming into cancer cells, but also protects can-
cer cells from cellular stress, enhances cancer cell survival
and is associated with cancer growth and progression [18].
Since these revelations, there has been no comprehensive
analysis of the expression level of Nrf2 in the nucleus of
gastric cancer cells, and there have been no studies aimed
at clarifying the relationship between the expression level
of Nrf2 in the nucleus of gastric cancer cells and clinical
outcome. In the current study, we carried out the first
examination of the expression level of Nrf2 in the nucleus
of gastric cancer cells and further discuss the clinical sig-
nificance of Nrf2 expression with respect to anti- oxidative
stress.
Methods
Detection of Nrf2 expression in gastric cancer cell lines by
Western blot analysis
The gastric carcinoma cell lines MKN74, MNK45, KATO-
III and NUGC4 were purchased from the Japanese
Physical and Chemical Institute, Tokyo, Japan. The cells
were incubated in RPMI 1640 with 10% fetal bovine
serum (FBS), 100 units/ml penicillin, and 100 μg/ml
streptomycin at 37°C in a cell incubator. All cells were
harvested by centrifugation, rinsed with phosphate buff-
ered saline (PBS) and total protein was extracted in lysis
buffer. Nuclear extracts and cytoplasmic fractions for
Western blotting of Nrf2 were prepared using a Nuclear/
Cytosol Fractionation Kit (K266-25, BioVison, California,
USA). Western blot analysis of Nrf2 expression in gastric
cancer cell lines was performed as follows. Denatured
protein extracted from the nucleus or cytoplasm was
separated on an SDS-polyacrylamide gel and transferred
to Hybond membrane, which was then blocked overnight
in 5% skim milk in Tris-buffered saline (TBS). The mem-
brane was then incubated with mouse monoclonal anti-
body against Nrf2 (sc-365949, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) at 1:500 dilution for overnight.
The membrane was rinsed with TBS-Tween 20 (TBST)
and incubated with anti-mouse IgG conjugated to horse-
radish peroxidase (HAF007, RD Syestems, Minneapolis,
USA) for 15 minutes. Immunoreactive bands were visual-
ized on X-ray film (Fuji, Japan) using ECL-Plus detection
reagents (RPN2132, GE Healthcare, Buckinghamshire,
England). Subsequently, to confirm nuclear and cytoplasmic
fractions, the membrane was washed with WB Stripping
Solution (Nakalai Tesque, Tokyo, Japan) for 15 minutes
and re-probed for nuclear and cytoplasmic markers using
the anti-Lamin B1 antibody (ab16048, Abcam, Cambridge,
USA, 1:1000) and the anti-α-Tubulin antibody (CP06,
Calbiochem, MA, USA, 1:1000) respectively.
Patients and specimens
This study included 175 patients with gastric adenocar-
cinoma that had invaded into submucosal layer or deeper.
All patients underwent curative gastrectomy with lymph
node dissection at Kagoshima University Hospital from
January 1995 to December 2004. Among 175 patients, 57,
14, 99, and 5 patients received distal, proximal, total and
partial gastrectomy, respectively. The male to female ratio
was 116 to 59, and the average age was 66 years, ranging
from 31 to 84 years. The number of patients with stage I,
II and III gastric cancers was 47, 33 and 95, respectively.
Histopathologically, 71 cases were differentiated (papillary,
well-differentiated and moderately differentiated tubular
adenocarcinoma) and 104 were undifferentiated (poorly
differentiated adenocarcinoma, mucinous adenocarcin-
oma and signet-ring cell carcinoma) carcinomas according
to the 7th edition of tumor node metastasis classification.
None of these patients received chemotherapy before
surgery. Written informed consent was obtained from
the patients and the study was approved by the Ethical
Committee of Kagoshima University Hospital (registra-
tion number 35–24). This investigation conformed to
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the principles outlined in the Declaration of Helsinki.
Clinicopathological findings are described according to
the 7th edition of tumor node metastasis classification.
Immunohistochemical analysis of Nrf2 in gastric cancer
and its evaluation
Tumor samples were fixed with 10% formaldehyde in PBS,
embedded in paraffin, sectioned into 4-μm thick sections
and mounted on glass slides for immunohistochemical ana-
lysis. Sections were deparaffinised in xylene and dehydrated
in a series of graded ethanol. The endogenous peroxidase
activity of the specimens was blocked by immersing the
slides in a 3% hydrogen peroxidase–methanol solution for
10 min at room temperature. After washing three times
with PBS (5 min per wash), the sections were treated with
1% bovine serum albumin for 30 min at room temperature
to block nonspecific reactions. For staining with anti-Nrf2
antibodies, sections were pretreated with citrate buffer for
10 min at 121°C in a microwave oven to retrieve antigenic-
ity. The sections were washed three times with PBS for
5 min each time, and were then blocked by treatment with
PBS containing 3% skim milk for 10 min at room
temperature. The blocked sections were incubated with the
diluted primary anti-Nrf2 antibody (sc-365949, Santa Cruz
Biotechnology, Inc., 1:200,) in PBS at 4°C overnight,
followed by staining with a streptavidin–biotin–peroxidase
kit (Nichirei, Tokyo, Japan). The sections were washed
three times in PBS for 5 min per wash, and the immune
complex was visualized by incubating the sections with di-
aminobenzidine tetra hydrochloride. The sections were
rinsed briefly in water, counterstained with hematoxylin,
and mounted. Noncancerous placental tissue was used
as the positive control for Nrf2. Nrf2 expression was
determined by counting the number of cancer cells in
which the nucleus was stained with the anti-Nrf2 anti-
body. All immunostained slides were evaluated by two
independent observers (YK and SI), who were unaware of
the clinical data and disease outcome. To evaluate Nrf2
expression, 10 representative fields within the tumor were
selected, and expression in a total of 1000 cancer cells
(100 cells per field) was evaluated using high power
Figure 1 Nuclear factor (erythroid-2)–related factor 2 (Nrf2) expression in gastric carcinoma cell lines. Nrf2 protein expression in nuclear
and cytoplasmic extracts of the gastric cell lines MKN74, MNK45, KATO-III, and NUGC4 was assayed by Western blotting. The blot was re-probed
with anti-Lamin B1 and anti-α-Tubulin antibodies that were used as positive controls for the nucleus and cytoplasm, respectively. Nuclear and
cytoplasmic fractions were clearly separated. The Nrf2 protein was identified mainly in the nucleus of all gastric cancer cell lines. Little Nrf2 was
detected in the cytoplasm.




















Stage was assessed according to 7th edition of tumor node metastasis classification.
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(×400) microscopy. In the case of coexistence of differenti-
ated and undifferentiated area in same section, we evalu-
ated the expression level of Nrf2 in the undifferentiated
area, even though the area of undifferentiated is smaller
than differentiated area. The average labeling index of
Nrf2 was assessed according to the proportion of positive
cells in each field. Expression of Nrf2 was assessed based
on both the proportion of positive cells and the intensity
of staining. The intensity of Nrf2 staining was quantified
using a three-value intensity score (0, 1+, or 2+). The
extent of reactivity was evaluated according to Solis et al.
[21] and was expressed as a percentage (0-100%). Immu-
nohistochemical scores, which ranged from 0 to 200, were
calculated by multiplying the values of the intensity and
the extent of reactivity. These scores were used to deter-
mine Nrf2 expression levels. Since the median score of
Nrf2 expression in gastric cancer was 110 in the present
study, a cut-off value of 100 was decided on.
Association between the expression level of Nrf2 in
gastric cancer and chemoresistance
To evaluate whether the expression level of Nrf2 in
gastric cancer affects chemoresistance, we compared the
expression level of Nrf2 in gastric cancer patients who
received 5-Fluorouracil (5FU) based adjuvant chemo-
therapy. We defined “5FU resistance” as gastric cancer
that recurred after adjuvant chemotherapy. As a standard
protocol, we administer 5FU-based adjuvant chemother-
apy to patients with stage II or III cancer. We excluded
patients who were not able to continue adjuvant chemo-
therapy due to side effects. As a result, 72 patients were
enrolled in this analysis.
Figure 2 Immunostaining of nuclear factor (erythroid-2)–related factor 2 (Nrf2) in clinical gastric cancer samples. Representative immunostaining
of Nrf2 in (a) Positive control, noncancerous placental tissue; (b) normal stomach tissue; (c – e) Gastric cancer tissues; (c) negative staining of Nrf2, (d) weak
staining (+1) of Nrf2, (e) strong staining (+2) of Nrf2 (original magnification, ×400). Expression of Nrf2 in clinical samples. Immunostaining of Nrf2 (original
magnification, ×400)
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Statistical analysis
Statistical analysis of group differences was performed
using the χ2 test, Fisher’s exact test and the Mann–Whitney
U test. The Kaplan-Meier method was used for survival
analysis, and differences in survival were estimated by using
the log-rank test. Prognostic factors were examined by
univariate and multivariate analyses (Cox proportional haz-
ards regression model). A p value < 0.05 was considered to
indicate statistical significance. All statistical analyses were
performed using the StatFlex version 6.0 for Windows soft-
ware (StatFlex version 6.0; Artec Inc., Osaka, Japan).
Results
Nrf2 expression in gastric carcinoma cell lines
The expression of Nrf2 in nuclear and cytoplasmic fractions
of gastric carcinoma cell lines was analyzed by Western
blotting. Nrf2 was expressed mainly in the nucleus of
all of the gastric cancer cell lines and little expression
was observed in the cytoplasm (Figure 1).
Nrf2 immunohistochemical expression in gastric cancer
and its association with clinicopathological features
We next determined the expression and subcellular
localization of Nrf2 in 175 paraffin-embedded archival
gastric cancer tissues, using immunohistochemistry. The
clinicopathological characteristics of the patients are shown
in Table 1. Nrf2 immunoreactivity was detected mainly in
the nucleus (Figure 2). Further evaluation of nuclear Nrf2
immunoreactivity indicated that the Nrf2 immunoreactive
pattern differed between differentiated gastric cancer cells
and undifferentiated gastric cancer cells in the same speci-
men. Thus, undifferentiated gastric cancer cells were more
likely to display positive Nrf2 immunoreactivity compared
to differentiated gastric cancer cells. Of the 175 patients,
108 (61.7%) displayed an Nrf2 immunohistochemical score
of greater than 100 and were classified as Nrf2 positive.
The remaining 67 (38.3%) patients were classified as the
Nrf2 negative group. Table 2 shows the correlation between
Nrf2 expression and clinicopathological features. Nrf2
positive expression was significantly associated with
gender, tumor size, tumor depth, lymph node metastases,
lymphovascular invasion, histologic classification and
clinical stage of gastric cancer.
Nrf2 immunohistochemical expression in gastric cancer
and its association with 5FU resistance
Table 3 shows the correlation between Nrf2 expression and
5FU resistance in the 72 patients who were treated with
5FU-based adjuvant chemotherapy. Of these 72 patients,
59 were Nfr2 positive and 13 were Nfr2 negative. Out of
the 59 Nfr2 positive patients, 43 (72.9%) patients were 5FU
resistant, whereas only 5 (38.5%) of the 13 Nrf2 negative
patients were 5FU resistant. The difference between the
percentage of Nrf2 positive and Nrf2 negative patients
in the 5FU resistance group was statistically significant
(p = 0.024).
Survival analysis
Kaplan Meier analysis indicated that the overall survival
of the Nrf2 positive group was significantly poorer than
that of the Nrf2 negative group (61% vs. 79% respectively)
(p < 0.01) (Figure 3).
Table 2 Correlation between expression of nuclear factor
(erythroid-2)–related factor 2 (Nrf2) and
clinicopathological factors
Clinical factors Expression of Nrf2 P-
valueNegative Positive
n = 67 (38.3%) n = 108 (61.7%)
Age n.s.






< 5 cm 36 27
≧5 cm 31 81
Tumor depth <0.01
T1a, T1b, T2 31 19
T3, T4a, T4b 36 89




IA, IB 28 19
IIA, IIB 12 21







Table 3 Correlation between expression of nuclear factor
(erythroid-2)–related factor 2 (Nrf2) and 5-Fluorouracil
(5FU) chemosensitivity
5FU sensitivity Expression of Nrf2 P- value
Negative Positive
Resistant 5 43 0.024
Sensitive 8 16
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In addition, tumor depth, tumor size, lymph node metas-
tases, histological classification, lymphovascular invasion
were also significant factors for survival based on univariate
analysis (Table 4).
We also performed multivariate analysis of these six
factors including Nrf2 as an independent prognostic
marker. Lymph node metastases was selected as inde-
pendent prognostic marker. However, Nrf2 expression
was not selected (Table 4).
Discussion
The antioxidant Nrf2, which functions to protect normal
cells from numerous damaging oxidative conditions, has
been considered to be a major cellular defense mechanism.
However, many papers have indicated the overexpression
of Nrf2 and its downstream genes in many types of human
cancer [19-25]. These reports showed that Nrf2 not only
protects normal cells from transforming into cancer cells,
but may also facilitate cancer cell proliferation and prolong
survival [18]. The present report is the first report to show
an association between the expression level of Nrf2 in the
nucleus of gastric cancer cells and clinicopathological
findings.
In the current study, Nrf2 immunoreactivity was detected
predominantly in the nucleus, not only in vivo but also
in vitro in a number of gastric cancer cell lines. It has been
speculated that persistent nuclear expression of Nrf2 in
gastric cancer cell lines results in the production of anti-
oxidants, which confer on these cancer cell lines a high
ability to resist reactive oxygen species (ROS). An similar
phenomenon was reported by Ma et al. for cervical cancer
tissue They reported that upstaging of cervical cancer
leads not only to a higher concentration of Nrf2 in the
nucleus of the cancer cells, but also to a higher
Figure 3 Postoperative outcomes of 175 gastric cancer patients according to nuclear factor (erythroid-2)–related factor 2 (Nrf2)
expression. Kaplan Meier analysis of the postoperative outcomes of 175 gastric cancer patients according to Nrf2 expression. Survival curves
were constructed for the 175 patients that were divided into Nrf2-positive and Nrf2-negative groups. The Nrf2-positive group had a significantly
poorer outcome than the Nrf2-negative group (p < 0.01).
Table 4 Univariate and multivariate analyses of prognostic factors in gastric cancer
Clinical factors Univariate Multivariate
p Multivariate P Hazard ratio 95% confidence interval
Age 0.42 - - -
Gender 0.50 - - -
Depth <0.01 0.25 2.44 0.52 - 11.44
Tumor size <0.01 0.35 1.58 0.61 - 4.09
Nodal involvement <0.01 0.03 5.02 1.18 - 21.41
Lymphovascular invasion <0.05 0.27 0.35 0.05-2.26
Histology <0.05 0.17 1.1.62 0.81 - 3.24
Nrf2 <0.05 0.40 1.37 0.66 - 2.87
Nrf2, nuclear factor (erythroid-2)–related factor 2.
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concentration of downstream antioxidant response pro-
teins [22]. It can therefore be theoretically proposed that
the gastric cancer cell lines with nuclear Nrf2 expression
would have a higher malignant potential through this
mechanism.
We immunohistochemically identified a high rate of
Nrf2 expression in gastric cancer clinical specimens
(Table 2). Thus, 61.7% of the specimens were Nrf2 posi-
tive, which was higher than the percentage of positive
specimens reported in non-small cell lung carcinoma
(26%) [21] or in gallbladder cancer (23%) [23].
Furthermore, there were significant correlations between
Nrf2 expression and several clinicopathological factors such
as tumor size, tumor depth, lymphatic invasion, lymph
node metastases, and tumor histology. Our findings are in
accordance with those of Wang et al. who reported that
expression of Nrf2 in gallbladder cancer was significantly
associated with differentiation, stage, and lymph node
metastases [23].
Recently Xiu-Freg Hu et al. similarly investigated Nrf2
expression in gastric cancer [26]. They also suggested a
prognostic significance of Nrf2 expression in accordance
with our results. However, they reported that Nrf2
immunoreactivity was detected in the cytoplasm but that
it was not detected in the nucleus. This different result
may be due to the fact that they used different antibodies
from the ones used in the present study. It has been well
documented that Nrf2 exerts its antioxidant ability only
when it translocates to the nucleus from the cytoplasm
[27]. Our immunoblotting analysis showed that Nrf2 was
predominantly present in the nucleus of the cells of gastric
cancer cell lines. We therefore considered that the persist-
ent overexpression of Nrf2 in the nucleus of gastric cancer
cells likely worked as an antioxidant that protected the
gastric cancer cells from ROS, and that Nrf2 nuclear
expression may reflect aggressive behavior of gastric can-
cer. Based on this theory, we considered it essential to
evaluate nuclear, but not cytoplasmic expression of Nrf2
in clinical specimens of gastric cancer.
In this study, we showed the prognostic value of Nrf2
expression by univariate analysis. Although Nrf2 positivity
was not selected as an independent prognostic marker by
multivariate analysis, this finding may be explained by the
possibility that Nrf2 positivity was significantly affected by
nodal involvement which was regarded as poor prognostic
factor. Solis et al. and Wang et al. similarly reported that
Nrf2 expression was associated with poor overall survival
in non-small cell lung carcinoma [21] and in gallbladder
cancer [23], respectively. These data suggest that Nrf2
expression might be used as a significant prognostic
parameter for prediction of the survival of postoperative
gastric cancer patients.
It has recently been reported that high Nrf2 expres-
sion may facilitate and prolong cancer cell survival
following anticancer chemotherapy and radiation ther-
apy [14,16,19-22,28-33]. Our results also showed that
positive Nrf2 expression was significantly associated
with resistance to 5FU based adjuvant chemotherapy.
These combined results may imply that, by evaluating the
expression level of Nrf2 in the nucleus of gastric cancer
cells, it might be possible to predict the best candidates
who can benefit from receiving not only adjuvant chemo-
therapy but also neoadjuvant chemotherapy.
Genetic or functional inhibition of Nrf2 has been shown
to result in the repression of cellular Nrf2 -regulated anti-
oxidant enzymes, including cellular glutathione, thiore-
doxin and non-protein thiols. Ultimately, these alterations
may restore the sensitivity of cancer cells to anticancer
drugs and radiation therapy. Thus, Cho et al. reported that
functional inhibition of Nrf2 leads to sensitization of can-
cer cells to alkylating anticancer agents [31]. Furthermore,
Ma et al. reported that the combination of cisplatin and
knockdown of Nrf2 dramatically and significantly inhib-
ited tumor growth in vivo [22].
Taking these evidences into account, it is very likely
that a new chemotherapeutic protocol that involves Nrf2
regulation will be introduced in the near future. For
example, the efficacy of chemotherapy could be first
predicted by evaluation of Nrf2 expression and, if any
of Nrf2 positive patients are assessed as being resistant
to chemotherapy, then it may be possible to achieve
sufficient efficacy of chemotherapy by concomitant inhib-
ition of Nrf2. Therefore a new chemotherapeutic protocol
that includes antioxidant therapy may be a useful method
for solving a clinical problem.
Conclusions
Nrf2 expression is closely associated with clinicopatholog-
ical factors and the prognosis of gastric cancer patients.
Nrf2 expression in gastric cancer may be useful for evalu-
ation of biological malignant potential, which may be
mediated in part by Nrf2 enhancement of the antioxidant
ability of gastric cancer cells. Antioxidant therapy might
be a promising approach for the treatment of Nrf2 posi-
tive gastric cancer patients.
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